Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zeria Pharmaceutical Co., Ltd.

https://www.zeria.co.jp/english/

Latest From Zeria Pharmaceutical Co., Ltd.

Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation

Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US. 

Financing Strategy

‘Femtech’ Evolving Beyond Periods, Pregnancy And Postpartum

Digital female-centric primary and preventive care and fertility support were top-funded women’s health segments in 2021, drawing $668m and $330m in investments, respectively. Going forward, experts anticipate innovation to address unmet needs related to menopause, vaginal microbiome, endometriosis, and other chronic conditions, and surgeries such as hysterectomies and mastectomies.

Commercial Companies

India CEOs On Automated Plants, New Modalities, Tackling 'The Great Talent Reshuffle'

The top leadership of Cipla, Dr Reddy’s Laboratories, Zydus Cadila, Sun Pharmaceutical Industries and Lupin discuss automation roadmaps, strategies for a play in new modalities and talent acquisition and retention amid the global "great resignation."

Commercial Strategy

Bill Gates Backs mRNA Capacity In India, Pitches Cutting Gene Therapy Cost

Billionaire philanthropist and co-chair of the Bill and Melinda Gates Foundation signals efforts underway to support building mRNA capacity in India amid the new platform’s potential beyond COVID-19 vaccines. He also highlights the need to bring down sharply the cost of gene therapies.

Research & Development Coronavirus COVID-19
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Tillotts Pharma AG IONA INTERNATIONAL CORPORATION Biofac Esbjerg A/S
UsernamePublicRestriction

Register